The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2024 | 5-year OS results of HIMALAYA: durvalumab + tremelimumab in unresectable hepatocellular carcinoma
Lorenza Rimassa, MD, IRCCS Humanitas Research Hospital, Milan, Italy, comments on the positive results of the HIMALAYA (NCT03298451) Phase III study, which showed that the combination of durvalumab plus tremelimumab (STRIDE regimen) significantly improves survival rates in patients with unresectable hepatocellular carcinoma, with 20% of patients alive at five years, compared to 9.4% in the sorafenib arm. Dr Rimassa highlights that stable disease or any degree of reduction in the disease is enough to achieve long-term survival, and that the regimen has shown no new treatment-related adverse events. This interview took place at the ESMO Asia Congress 2024, held in Singapore, Republic of Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
